Every material Form 8-K Werewolf Therapeutics, Inc. has filed with the SEC since July 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Werewolf Therapeutics released early clinical data for its two INDUKINE candidates, WTX-124 and WTX-330, presented at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. The company said it has aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for WTX-124 and that WTX-330 was well tolerated. The filing contains no financial results, and the data come from small early-stage trials, so shareholders will mainly weigh the programs' future development prospects.
WTX-124 recommended Phase 2 dose set at 18 mg IV Q2W, aligned with the FDA, for monotherapy and combination with pembrolizumab
WTX-124 monotherapy produced one durable confirmed complete response in a patient with ICI-resistant cutaneous squamous cell carcinoma, ongoing for approximately three years
WTX-330 data from 24 patients showed a confirmed partial response in a patient with gallbladder cancer, per the filing
On August 21, 2026, Werewolf Therapeutics agreed to merge with Ambros Therapeutics, a clinical-stage biotechnology company developing neridronate for CRPS-1, in an all-stock transaction. Pre-merger Werewolf stockholders, other than private placement investors, are expected to own about 6.8% of the combined company, so the merger would substantially dilute their holdings. The deal is expected to close by the first quarter of 2027, subject to stockholder approvals, Nasdaq listing approval, an effective Form S-4 and other conditions.
Pre-merger Ambros stockholders are expected to own about 71.7% of the combined company, and private placement investors about 21.5%.
Implied valuations are $500.0 million for Ambros and $47.5 million for Werewolf.
A concurrent private placement of $150 million in gross proceeds is expected to close with the merger.
Termination fees are $20.0 million payable by Ambros and $1.9 million payable by Werewolf in certain circumstances.
On August 14, 2026, Werewolf Therapeutics agreed to sell its pre-clinical INDUCER and INDUKINE platform technology to EMD Serono, with EMD paying $28.0 million upfront and an additional $5.0 million upon completion of the technology transfer. The company keeps its WTX-124 and WTX-330 clinical programs and received an exclusive license to certain patents needed to develop them, but it agreed to a 24-month non-competition covenant on certain related compounds.
Upfront consideration of $28.0 million, plus an additional $5.0 million upon completion of the technology transfer
Sold INDUCER and INDUKINE pre-clinical platforms and related compounds, excluding the WTX-124 and WTX-330 clinical programs
Company retains rights to continue developing WTX-124 and WTX-330
Non-competition covenant for 24 months after closing, with customary exceptions for change of control transactions
Werewolf Therapeutics reported second quarter 2026 net income of $3.7 million, compared with a net loss of $18.0 million a year earlier, driven by $21.0 million of collaboration revenue tied to the sale of its JZP898 program to Jazz Pharmaceuticals Ireland Limited. Cash and cash equivalents fell to $22.0 million at June 30, 2026, and the company expects to fund operations into the second quarter of 2027, so shareholders should weigh the one-time revenue against the lower cash balance and the ongoing strategic alternatives process.
Net income was $3.7 million for Q2 2026, versus a net loss of $18.0 million in Q2 2025.
Collaboration revenue was $21.0 million in Q2 2026, from the JZP898 asset sale to Jazz; no collaboration revenue was recognized in Q2 2025.
Cash and cash equivalents were $22.0 million at June 30, 2026, down from $46.5 million at March 31, 2026; the company expects to fund operations into Q2 2027.
The company is running a strategic alternatives process with Piper Sandler & Co. and expects updates in the second half of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Werewolf Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →